Sagna Yempabou, Bagbila W P Abraham H, Sawadogo Nongoba, Savadogo Pouikomba Patrice C, Zoungrana Lassane, Séré Lassina, Yanogo A Donald R, Saloukou K Ella Manuella, Zemba Daniel, Zio Gael U, Zombre Yacine T, Millogo Roland, Traoré Solo, Ilboudo Alassane, Bognounou Réné, Ouedraogo N Christel J, Nikiema Péré, Bengaly Seydou, Gilberte Kyelem Carole, Guira Oumar, Maniam Jayanthi, Ogle Graham D, Ouedraogo Macaire S, Drabo Joseph Y
Service de Médecine Interne CHU Sourô Sanou, Bobo-Dioulasso, Burkina Faso; INSSA, Université Nazi BONI, Bobo-Dioulasso, Burkina Faso.
Service de Médecine Interne CHU Sourô Sanou, Bobo-Dioulasso, Burkina Faso; INSSA, Université Nazi BONI, Bobo-Dioulasso, Burkina Faso.
Diabetes Res Clin Pract. 2024 Jan;207:111086. doi: 10.1016/j.diabres.2023.111086. Epub 2024 Jan 3.
There are no data on type 1 diabetes (T1D) incidence and prevalence in Burkina Faso. We aimed to determine these in persons aged <25 years (y) since the implementation of Life for a Child (LFAC) program in 2013.
Data were collected from the prospective program register. Diagnosis of T1D was clinical, based on presentation, abrupt onset of symptomatic hyperglycemia, need for insulin replacement therapy from diagnosis, and no suggestion of other diabetes types.
We diagnosed 312 cases of T1D <25y in 2013-2022. Male-to-female ratio was 1:1. T1D incidence <25y per 100,000 population/year increased from 0.08 (CI 95% 0.07-0.60) in 2013 to 0.34 (CI 95% 0.26-0.45) in 2022 (p=0.002). Incidence <15y/y rose from 0.04 (CI 95% 0.01-0.10) to 0.27 (CI 95% 0.18-0.38) per 100,000/year in 2013 and 2022, respectively (p < 0.002). Prevalence per 100,000 population <25y was 0.27 (CI 95% 0.19-0.37) in 2013 and rose to 1.76 (CI 95% 1.546-1.99) in 2022 (p<0.0001). Mortality rate was 20 (CI 95% 13-29.6) per 1,000-person y.
There is a low but sharply rising T1D incidence and prevalence rates in children and youth in Burkina Faso since LFAC program implementation. It is very likely this is partly due to improved case detection. Mortality remains substantial.
布基纳法索尚无1型糖尿病（T1D）发病率和患病率的数据。我们旨在确定自2013年实施“儿童生命”（LFAC）项目以来，25岁以下人群的这些数据。
数据收集自前瞻性项目登记册。T1D的诊断基于临床表现，即症状性高血糖的突然发作、诊断后需要胰岛素替代治疗，且无其他糖尿病类型的迹象。
2013年至2022年期间，我们诊断出312例25岁以下的T1D病例。男女比例为1:1。每10万人口/年25岁以下T1D的发病率从2013年的0.08（95%置信区间0.07 - 0.60）增至2022年的0.34（95%置信区间0.26 - 0.45）（p = 0.002）。每10万人口/年15岁以下的发病率分别从2013年的0.04（95%置信区间0.01 - 0.10）升至2022年的0.27（95%置信区间0.18 - 0.38）（p < 0.002）。每10万25岁以下人口的患病率在2013年为0.27（95%置信区间0.19 - 0.37），2022年升至1.76（95%置信区间1.546 - 1.99）（p < 0.0001）。死亡率为每1000人年20例（95%置信区间13 - 29.6）。
自LFAC项目实施以来，布基纳法索儿童和青少年中T1D的发病率和患病率虽低但急剧上升。很可能部分原因是病例检测有所改善。死亡率仍然很高。
